SouthState Corp’s NovoCure NVCR Stock Holding History

SouthState Corp’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20	Closed	-$356	–	1519
2025 Q2	$356	Sell	20 -36	-64%	-$627	﹤0.01%	1492
2025 Q1	$999	Buy	+56	New	+$1.27K	﹤0.01%	1342

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SouthState Corp's NVCR Position: Q3 2025 in Review

SouthState Corp sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 20 shares — an estimated $356 sold.

SouthState Corp first reported a position in NVCR in Q1 2025 and held it in 2 quarters. The position peaked at $999 in Q1 2025. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

SouthState Corp reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
SouthState Corp sold 20 NovoCure shares in Q3 2025, an estimated $356.
SouthState Corp first reported a position in NovoCure in Q1 2025 and held it in 2 quarters.
SouthState Corp's NovoCure position peaked at $999 in Q1 2025.
244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on SouthState Corp's 13F filing for Q3 2025, filed 5 Nov 2025.